ArticleJournal of immunology (Baltimore, Md. : 1950)2022
Microfluidic Squeezing Enables MHC Class I Antigen Presentation by Diverse Immune Cells to Elicit CD8
Open access · bronzeAbstract read
In one paragraph
Article in Journal of immunology (Baltimore, Md. : 1950), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- B Cells and Tumor Immunometabolism: Emerging Insights into Immune Regulation and Therapeutic Resistance.Antibodies (Basel, Switzerland) · 2026Review
- Microfluidics for cell therapy and manufacturing in oncology and regenerative medicine.Lab on a chip · 2026Review
- Extracellular matrix stiffness in hepatocellular carcinoma: mechanisms and targeted therapeutic strategies.Frontiers in immunology · 2026Review
- Comparison of Current Immunotherapy Approaches and Novel Anti-Cancer Vaccine Modalities for Clinical Application.International journal of molecular sciences · 2025Review
- Review: radiotherapy-mediated B cells within the TLS influence the tumor microenvironment.Journal for immunotherapy of cancer · 2025Review
- Mechanical interactions impact the functions of immune cells and their application in immunoengineering.Advanced therapeutics · 2025Article
- Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.Molecular carcinogenesis · 2024Article
- Biophysical Control of the Glioblastoma Immunosuppressive Microenvironment: Opportunities for Immunotherapy.Bioengineering (Basel, Switzerland) · 2024Review
- Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.Lab on a chip · 2023Article
- Microfluidic cell squeeze-based vaccine comes into clinical investigation.NPJ vaccines · 2023Article
- Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.Investigational new drugs · 2023Article
- Mechanical stimulation on a microfluidic device to highly enhance small extracellular vesicle secretion of mesenchymal stem cells.Materials today. Bio · 2023Article
- Cell Squeeze: driving more effective CD8 T-cell activation through cytosolic antigen delivery.Immuno-oncology technology · 2022Review
- Review
- Engineered red blood cells (activating antigen carriers) drive potent T cell responses and tumor regression in mice.Frontiers in immunology · 2022Article
- Human Papillomavirus-Directed Therapeutics for Human Papillomavirus-Associated Oropharyngeal Cancer.Cancer journal (Sudbury, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 4 institutions in 2 countries.
Matthew G BootySQZ Biotechnologies, Watertown, MA.ORCID 0000-0002-0835-3439
Kelan A HlavatySQZ Biotechnologies, Watertown, MA.ORCID 0000-0002-4464-0208
Adam StockmannSQZ Biotechnologies, Watertown, MA.ORCID 0000-0002-5222-3156
Emrah Ilker OzaySQZ Biotechnologies, Watertown, MA.
Carolyne SmithSQZ Biotechnologies, Watertown, MA.ORCID 0000-0001-6132-6547
Lina TianSQZ Biotechnologies, Watertown, MA.
Edylle HowSQZ Biotechnologies, Watertown, MA.
Disha SubramanyaSQZ Biotechnologies, Watertown, MA.
Anita VenkitaramanSQZ Biotechnologies, Watertown, MA.
Christian YeeSQZ Biotechnologies, Watertown, MA.
Olivia PryorSQZ Biotechnologies, Watertown, MA.
Kelly VolkSQZ Biotechnologies, Watertown, MA.
Katarina BlagovicSQZ Biotechnologies, Watertown, MA.
Ildefonso Vicente-SuarezSQZ Biotechnologies, Watertown, MA.
Defne YararSQZ Biotechnologies, Watertown, MA.
Melissa MyintSQZ Biotechnologies, Watertown, MA.ORCID 0000-0003-1665-9451
Amy MerinoSQZ Biotechnologies, Watertown, MA.ORCID 0000-0002-1041-8975
Jonathan ChowSQZ Biotechnologies, Watertown, MA.ORCID 0000-0002-4321-2420
Tarek AbdeljawadSQZ Biotechnologies, Watertown, MA.
Harry AnSQZ Biotechnologies, Watertown, MA.
Sophia LiuDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0003-3614-9731
Shirley MaoDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA.
Megan HeimannDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0001-8973-6409
LeeAnn TalaricoSQZ Biotechnologies, Watertown, MA.
Miye K JacquesSQZ Biotechnologies, Watertown, MA.
Eritza ChongSQZ Biotechnologies, Watertown, MA.
Lucas PomeranceSQZ Biotechnologies, Watertown, MA.
John T GonzalezSQZ Biotechnologies, Watertown, MA.ORCID 0000-0002-1020-8783
Ulrich H von AndrianDepartment of Immunology, Harvard Medical School, Boston, MA.ORCID 0000-0003-4231-2283
Klavs F JensenDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0001-7192-580X
Robert LangerDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA.ORCID 0000-0003-4255-0492
Hendrik KnoetgenRoche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland; and.
Christine TrumpfhellerRoche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Schlieren, Switzerland.
Pablo UmañaRoche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development, Schlieren, Switzerland.
Howard BernsteinSQZ Biotechnologies, Watertown, MA.
Armon ShareiSQZ Biotechnologies, Watertown, MA.
Scott M LoughheadSQZ Biotechnologies, Watertown, MA; scott.loughhead@sqzbiotech.com.
SQZ Biotech (United States) · USMassachusetts Institute of Technology · USRoche (Switzerland) · CHHarvard University · US
Funding
Applications of a robust, vector-free intracellular delivery platform for immune cellsR44GM112259 · NIGMS · SQZ BIOTECHNOLOGIES COMPANY, INC. · PI BERNSTEIN, HOWARD, LOUGHHEAD, SCOTT MCNABB · 2017 to 2018
$1.7MNIGMS NIH HHS R44 GM112259
Abstract
CD8
Indexed as
Antigen PresentationMicrofluidicsAdoptive TransferAnimalsAntigen-Presenting CellsAntigens, NeoplasmCD8-Positive T-LymphocytesCell Culture TechniquesFemaleHistocompatibility Antigens Class IHumansImmunizationImmunophenotypingLeukocytes, MononuclearLymphocytes, Tumor-InfiltratingMiceAntigens, NeoplasmHistocompatibility Antigens Class I
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.